Company news: Celgene

Share this article:
The FDA expanded the indication for Celgene's drug Abraxane Friday when it approved the injection for use as a first-line treatment for advanced non-small cell lung cancer. The FDA first approved Abraxane for treatment of metastatic breast cancer in 2005 among patients for whom combination chemotherapy did not work. Reuters noted that the drug maker is also seeking additional indications, including pancreatic and skin cancers. Reuters said a Barclays analyst projected that Abraxane could have peak annual lung cancer sales of $110 million.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.